Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival.
biomarkers
circulating inflammatory markers
geriatric oncology
immune checkpoint inhibitors
systemic immune-inflammatory index
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Oct 2023
19 Oct 2023
Historique:
received:
18
09
2023
revised:
10
10
2023
accepted:
16
10
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Geriatric patients (≥80 years) are underrepresented in immune checkpoint inhibitor (ICIs) clinical trials. However, their unique biology may affect their response to ICIs. There are currently no established biomarkers of the response to ICIs in adult patients with cancer that can help with patient selection. We built a multicenter, international retrospective study of 885 patients (<80 years: n = 417, 47.12%; ≥80 years: n = 468, 52.88%) with different tumor types treated with ICIs between 2011 and 2021 from 11 academic centers in the U.S. and Europe. The main outcome measures were objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) stratified by age and circulating inflammatory levels (neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII)). Patients ≥80 years with low NLR (NLR-L) and SII (SII-L) had significantly higher ORR (vs. high NLR [NLR-H], Lower inflammation pre-ICI initiation may predict an improved response and survival in geriatric patients with cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Geriatric patients (≥80 years) are underrepresented in immune checkpoint inhibitor (ICIs) clinical trials. However, their unique biology may affect their response to ICIs. There are currently no established biomarkers of the response to ICIs in adult patients with cancer that can help with patient selection.
METHODS
METHODS
We built a multicenter, international retrospective study of 885 patients (<80 years: n = 417, 47.12%; ≥80 years: n = 468, 52.88%) with different tumor types treated with ICIs between 2011 and 2021 from 11 academic centers in the U.S. and Europe. The main outcome measures were objective response rates (ORR), progression-free survival (PFS) and overall survival (OS) stratified by age and circulating inflammatory levels (neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII)).
RESULTS
RESULTS
Patients ≥80 years with low NLR (NLR-L) and SII (SII-L) had significantly higher ORR (vs. high NLR [NLR-H],
CONCLUSION
CONCLUSIONS
Lower inflammation pre-ICI initiation may predict an improved response and survival in geriatric patients with cancer.
Identifiants
pubmed: 37894419
pii: cancers15205052
doi: 10.3390/cancers15205052
pmc: PMC10605297
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Treat Rev. 2016 Apr;45:30-7
pubmed: 26946217
Clin Cancer Res. 2018 Nov 1;24(21):5347-5356
pubmed: 29898988
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Clin Cancer Res. 2019 Jul 1;25(13):3839-3846
pubmed: 30967420
Cancers (Basel). 2022 Oct 27;14(21):
pubmed: 36358716
Vaccine. 2000 Feb 25;18(16):1717-20
pubmed: 10689155
J Immunother Cancer. 2018 Jan 22;6(1):5
pubmed: 29353553
Ann Transl Med. 2019 Sep;7(18):433
pubmed: 31700869
J Gerontol A Biol Sci Med Sci. 2014 Jun;69 Suppl 1:S4-9
pubmed: 24833586
Cancer Res Treat. 2021 Jul;53(3):671-677
pubmed: 33285051
Curr Opin Immunol. 2014 Aug;29:105-11
pubmed: 24934647
Melanoma Res. 2013 Apr;23(2):132-7
pubmed: 23344159
Cancer Immunol Immunother. 2015 Dec;64(12):1531-9
pubmed: 26392296
J Cell Mol Med. 2020 Mar;24(5):2993-3021
pubmed: 31989747
Arch Immunol Ther Exp (Warsz). 2016 Jun;64(3):249-54
pubmed: 26283530
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
J Cancer. 2018 Sep 7;9(18):3295-3302
pubmed: 30271489
Cancers (Basel). 2021 Dec 31;14(1):
pubmed: 35008350
Nat Immunol. 2018 Jan;19(1):10-19
pubmed: 29242543
World J Gastroenterol. 2017 Sep 14;23(34):6261-6272
pubmed: 28974892
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Rev Endocrinol. 2018 Oct;14(10):576-590
pubmed: 30046148
JAMA Oncol. 2021 Dec 01;7(12):1856-1861
pubmed: 34734989
Annu Rev Pathol. 2021 Jan 24;16:223-249
pubmed: 33197221
Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
Cancer. 2022 Aug 15;128(16):3067-3079
pubmed: 35727053
J Clin Lab Anal. 2019 Oct;33(8):e22964
pubmed: 31282096
Chin J Cancer. 2017 Sep 12;36(1):75
pubmed: 28899420